Email Updates

You are here

Home

4 FEBRUARY 2022 VOLUME 24 ISSUE 5

Media Coverage

  • CDC Data Shows Major Disparities in Black People With HIV Infections

    Black people account for a much higher proportion of new HIV infections compared to other races and ethnicities, and a majority of them reside in residentially segregated and vulnerable areas, according to new data released Thursday from the Centers for Disease Control and Prevention (CDC).

    February 4, 2022
    General
    The Hill

  • Inadequate HIV Testing of Children Across 7 African Nations

    Significant progress has been made to prevent vertical (mother-to-child) transmission of HIV. However, testing is still severely lacking among HIV-exposed infants and children. As such, there is little data on the proportion of undiagnosed children living with HIV.

    February 3, 2022
    General
    Contagion Live

  • ‘VB’ Is a New and More Infectious Variant of HIV – But It Is Treatable

    A more transmissible and potentially dangerous variant of HIV has been found in Europe. The discovery means it is more important than ever for people at higher risk to test for the virus regularly and to start treatment immediately, say doctors. The number of new HIV infections – all known variants combined – has fallen globally over the past decade, thanks to widespread use of medicines that suppress the virus. The new variant, called VB, is just as treatable as ordinary HIV and can be detected using the same diagnostic tests used for other HIV variants.

    February 3, 2022
    Treatment
    New Scientist

  • FDA Approves 2-Month Dosing of Injectable HIV Drug Cabenuva

    The US Food and Drug Administration (FDA) has approved rilpivirine and cabotegravir (Cabenuva) to 2-month dosing for adults living with HIV-1 infection. Cabenuva was first approved by the FDA in January 2021 to be administered once monthly to treat HIV-1 infection in virologically suppressed adults. The medication was the first injectable complete antiretroviral regimen approved by the FDA.

    February 2, 2022
    Treatment
    Medscape

  • HIV PrEP Access May Be Limited by States’ Prescriber Laws

    Each state has “scope of practice” laws that determine the extent to which nurse practitioners (NPs) and physician assistants (PAs) can diagnose conditions and prescribe medications. A recent study, published in the Journal of the Association of Nurses in AIDS Care (JANAC), found that stricter state laws that require medical doctors (MDs) to decide NP and PA autonomy may hinder the number of patients using HIV pre-exposure prophylaxis (PrEP).

    February 2, 2022
    PrEP
    Contagion Live

  • Queer Activists Are Making Sex Safer Because No One Else Will

    If they gave out gold stars for sex, Jody Jollimore would have one. Not for technique or frequency, per se, but for going above and beyond to protect himself and his partners from a range of sexually transmitted and blood borne infections (STBBIs).

    February 2, 2022
    General
    Xtra Magazine

  • HIV Stigma Persists Globally, According to Harris Poll

    Four decades into the AIDS epidemic and for some, it's as if gains in awareness, advances in prevention and treatment, and the concept of undetected equals untransmissable (U=U) never happened. In its place, people living with HIV continue to face discrimination and stigma that affect nearly every aspect of the care continuum, from testing, prevention, and treatment to linkage to sexual, health, and reproductive services.

    February 1, 2022
    General
    Medscape

  • HIV Prevention Injection: What You Need To Know About SA’s ‘Game-Changer’

    The ball is rolling as South Africa prepares to make the HIV prevention injection a reality in a country where close to eight million people are living with the virus. Approved by the US Food and Drug Administration (FDA) last month, National Department of Health spokesperson, Foster Moahle, said an application has been submitted to obtain the new long-acting injectable cabotegravir (CAB-LA). The department is waiting for approval from the South African Health Products Authority (SAHPRA).

    January 31, 2022
    PrEP
    Health-E News

  • Governments Are ‘Trying To Muzzle WHO,’ Says HIV Activist

    The world missed the global targets for HIV in 2020, including having fewer than 500,000 new HIV infections. But last week, several countries refused to move forward with the draft global health sector strategies on HIV, viral hepatitis, and sexually transmitted infections unless certain terminologies were removed from the draft.

    January 31, 2022
    General
    Devex

  • Long-Acting Injectable for HIV Prevention ‘Overpriced’

    While the long-acting injectable Apretude was more effective at reducing the incidence of HIV than oral emtricitabine-tenofovir disoproxil fumarate, researchers said it does not justify the higher costs associated with it.

    January 31, 2022
    PrEP
    Healio

  • Men Who Pay for Sex May Be Key to Spread of HIV

    Twenty years’ worth of surveys suggest that nearly one in ten sexually active men in 35 countries in sub-Saharan Africa have been clients of sex workers. These men are about 50 percent more likely to be living with human immunodeficiency virus (HIV), according to the researchers.

    January 31, 2022
    General
    Futurity

  • Private Sector Stakeholders To Launch N62.1 Billion HIV Trust Fund of Nigeria

    All is set for the launch of the private sector-led N62.1 Billion (US$150 Million) HIV Trust Fund of Nigeria (HTFN). Recommended by Nigeria’s National Agency for the Control of AIDS (NACA) and driven by the Nigeria Business Coalition Against AIDS (NiBUCAA), the HTFN is a sustainable financing mechanism for the mobilization and deployment of domestic private sector resources to address the Prevention of Mother to Child Transmission (PMTCT) of HIV in Nigeria.

    January 30, 2022
    Treatment
    Vanguard

  • What’s in the HIV Treatment Pipeline for 2022 and 2023?

    When it comes to the HIV treatment landscape, 2021 wasn’t exactly a seismic year. Not like, say, 1996, when the lifesaving protease-driven “cocktail” treatment broke through. The biggest treatment advance in 2021 was probably the US Food and Drug Administration (FDA) approval of Cabenuva (cabotegravir/rilpivirine), the first long-acting HIV treatment, which requires a monthly injection (at most) at your provider’s office.

    January 28, 2022
    Treatment
    The Body

  • Migration Impacts Treatment Access for Women in South Sudan Who Sell Sex

    Researchers surveyed around 1,250 women (aged 15 and above) in Juba, the capital, and Nimule, a city that borders Uganda. All received money, goods or services in exchange for sex. Participants were described as sex workers if they were aged 18 and above or sexually exploited if aged 15-17 (described here as ‘women who sell sex’).

    January 28, 2022
    Treatment
    Avert

  • Model that Decriminalized Drugs, Invests Savings Shows Reduction in HIV Transmission

    Moving to a system that decriminalizes drugs and invests the money saved into programs that increase antiretroviral therapy (ART) and opioid agonist therapy would be ultimately a cost-saving strategy and reduce HIV transmission, according to a paper published in The Lancet HIV.

    January 28, 2022
    General
    Contagion Live

  • HIV mRNA Vaccine Trial Is Now Underway

    The first doses of an experimental HIV vaccine regimen using the same messenger RNA (mRNA) technology as highly effective COVID-19 vaccines have been administered to clinical trial participants, according to an announcement​ from Moderna and the ​International AIDS Vaccine Initiative (IAVI).

    January 28, 2022
    HIV Vaccine
    POZ

Published Research

Announcements